読み込み中
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
前日終値
$3.39
+$0.22 · +6.94%
日中の時刻はETです。市場データは遅延する場合があります。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日中レンジ
現在 $3.39
52週レンジ
現在 $3.39
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
61
強気
リスク
45
やや高いリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
日中レンジ
現在 $3.39
52週レンジ
現在 $3.39
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 74.46万 USD | 4617.55万 USD | 5480.7万 USD | 1.13億 USD | 9062.16万 USD |
| 販売・一般管理 | 31.19万 USD | 3771.55万 USD | 4889.5万 USD | 4792.61万 USD | 3508.19万 USD |
| 営業費用 | 5910.02万 USD | 8389.1万 USD | 1.04億 USD | 1.61億 USD | 1.26億 USD |
| 受取利息 | 139.6万 USD | 353万 USD | 515.17万 USD | 265.9万 USD | 119.91万 USD |
| 減価償却費と償却費 | — | — | 1.04億 USD | 2000 USD | 1258 USD |
| 営業利益 | −5910.02万 USD | −8389.1万 USD | −1.04億 USD | −1.61億 USD | −1.26億 USD |
| 純利益 | −5738.52万 USD | −7997.94万 USD | −9879.2万 USD | −1.57億 USD | −1.26億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1382.03万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM788.84万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF530.9万0.01%954億 USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH375万0.81%4.62億 USD0.35%$64.65+1.60%
iShares Russell 2000 Growth ETFIWO273.32万0.02%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO236.71万0.01%180億 USD0.06%$112.66+0.50%
AdvisorShares Psychedelics ETFPSIL211.26万4.51%4685.29万 USD1.84%$21.765+3.69%
Vanguard Health Care ETFVHT107.92万0.00%220億 USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAdvisorShares Psychedelics ETFPSILVanguard Health Care ETFVHTAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
